NDC 70771-1087-2 - oxybutynin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70771-1087
- Requested NDC
- 70771-1087-2
- Package NDCs from labels
- 70771-1087-6, 70771-1087-1, 70771-1087-9, 70771-1087-5, 70771-1087-3, 70771-1087-2, 70771-1087-4
- Manufacturer
- Zydus Lifesciences Limited
- Effective date
- 2024-12-03
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| oxybutynin - Zydus Lifesciences Limited | Zydus Lifesciences Limited | 2024-12-03 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70771-1087-1 | oxybutynin | 100 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 100 | 8 | |
| 70771-1087-2 | oxybutynin | 10 in 1 BLISTER PACK | TABLET, FILM COATED, EXTENDED RE | 10 | 8 | |
| 70771-1087-3 | oxybutynin | 30 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 30 | 8 | |
| 70771-1087-4 | oxybutynin | 10 in 1 CARTON | TABLET, FILM COATED, EXTENDED RE | 10 | 8 | |
| 70771-1087-5 | oxybutynin | 500 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 500 | 8 | |
| 70771-1087-6 | oxybutynin | 60 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 60 | 8 | |
| 70771-1087-9 | oxybutynin | 90 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 90 | 8 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70771-1087 | OXYBUTYNIN TABLET, FILM COATED, EXTENDED RELEASE [ZYDUS LIFESCIENCES LIMITED] | 8 | Current NDC, Legacy NDC, 7 package rows | 20241206_f405a774-bd91-4513-b7c7-c44f0596d988.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TopCare Health Advanced Moisturizing Plus Redness Relief | DEXTRAN 70, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL | Topco Associates LLC | 9c6193a6-d822-1b27-e053-2995a90ab3cf | 2023-12-20 | Warnings | FZ989GH94E |
| HEB Advanced Eye Drops | DEXTRAN 70, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HYDROCHLORIDE | HEB Grocery Company, LP | f76281d6-3aea-349b-e053-6394a90afca2 | 2023-12-20 | Warnings | FZ989GH94E |
| GenTeal Tears (Moderate) | DEXTRAN 70, GLYCERIN, HYPROMELLOSE | Alcon Laboratories, Inc. | a2992597-3490-6a5c-be45-2b6fa15e1547 | 2023-12-15 | Warnings | 3NXW29V3WO |
| Good Neighbor Pharmacy Artifical Tears Lubricant Eye Drops | POLYVINYL ALCOHOL, POVIDONE | Proficient Rx LP | 73e12596-6dd5-4cd2-83ed-992e1211b4b8 | 2023-12-01 | Warnings | FZ989GH94E |
| oxybutynin | OXYBUTYNIN | Zydus Pharmaceuticals USA Inc. | c042bf06-79a3-4dc7-ae05-3ef3cfae9d44 | 2023-11-07 | Warnings, Adverse reactions | ANDA202332 863636 863619 863628 L9F3D9RENQ |
| OXYBUTYNIN CHLORIDE | OXYBUTYNIN CHLORIDE | A-S Medication Solutions | 83522acd-0ecc-46ac-a018-a3205ba096ff | 2023-11-01 | Warnings, Adverse reactions | L9F3D9RENQ |
| OXYBUTYNIN CHLORIDE | OXYBUTYNIN CHLORIDE | NCS HealthCare of KY, LLC dba Vangard Labs | 5b72d34e-ae57-4459-ba2c-3bae8a69c5c1 | 2023-10-04 | Warnings, Adverse reactions | L9F3D9RENQ |
| Anubis Barcelona Vital Line | HYDROLYZED COLLAGEN | ANUBIS COSMETICS SL | f564bbf0-3b5c-4a81-e053-2a95a90a7ea6 | 2023-08-29 | Warnings | ZF94AP8MEY |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | 02ff3be7-fc5c-4b91-8c67-ecdf6e19c42a | 2023-05-31 | Warnings, Adverse reactions | 863636 863619 863628 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | d2bb6927-5fbf-49ca-a891-d701bff1c812 | 2023-05-31 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | Lannett Company, Inc. | c5950dba-d92b-46a0-993f-af9f9ddb52bf | 2023-05-30 | Warnings, Adverse reactions | 863636 863619 863628 L9F3D9RENQ |
| oxybutynin | OXYBUTYNIN | A-S Medication Solutions | 1f95920c-5dc2-44e4-b61d-b2c5e05390ba | 2023-02-06 | Warnings, Adverse reactions | ANDA202332 863619 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Amneal Pharmaceuticals LLC | 53924eba-1919-4203-9a1e-d57dfdd3b963 | 2023-02-02 | Warnings, Adverse reactions | 863636 863619 863628 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | 1e1c1043-e4c5-4a06-9cc1-45d4397746f4 | 2023-01-04 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Proficient Rx LP | e3f0c249-8085-4979-823a-820e233a284f | 2022-06-01 | Warnings, Adverse reactions | L9F3D9RENQ |
| oxybutynin chloride | OXYBUTYNIN CHLORIDE | Proficient Rx LP | 88f08450-559e-4038-aad1-051e4ab283cf | 2022-06-01 | Warnings, Adverse reactions | 863619 L9F3D9RENQ |
| OXYBUTYNIN CHLORIDE | OXYBUTYNIN CHLORIDE | Leading Pharma, LLC | b73b8338-8045-448f-87a6-3d289227d00e | 2022-02-14 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Lannett Company, Inc. | 615f3d95-197c-4fec-b81f-c26449c93c3b | 2020-02-21 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | e985e201-2fb3-4781-9790-a1a3db1ae2a1 | 2017-10-20 | Warnings, Adverse reactions | 863636 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | 58136f28-70c1-4cf2-bcd7-858c5609431a | 2016-06-15 | Warnings, Adverse reactions | L9F3D9RENQ |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.